254 related articles for article (PubMed ID: 25457974)
1. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.
Funakoshi T; Lee CH; Hsieh JJ
Cancer Treat Rev; 2014 May; 40(4):533-47. PubMed ID: 24398141
[TBL] [Abstract][Full Text] [Related]
3. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers in advanced renal cell carcinoma.
Maroto P; Rini B
Clin Cancer Res; 2014 Apr; 20(8):2060-71. PubMed ID: 24526734
[TBL] [Abstract][Full Text] [Related]
5. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
6. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
8. Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar I; Dhillon J; Pili R
Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
10. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
[TBL] [Abstract][Full Text] [Related]
11. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Powles T
Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
[No Abstract] [Full Text] [Related]
12. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
Djordjevic G; Mozetic V; Mozetic DV; Licul V; Ilijas KM; Mustac E; Oguic R; Fuckar Z; Jonjic N
Pathol Res Pract; 2007; 203(2):99-106. PubMed ID: 17270362
[TBL] [Abstract][Full Text] [Related]
13. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.
Rajandram R; Bennett NC; Morais C; Johnson DW; Gobe GC
Med Hypotheses; 2012 Feb; 78(2):330-6. PubMed ID: 22153576
[TBL] [Abstract][Full Text] [Related]
15. The role of pharmacogenomics in metastatic renal cell carcinoma.
Castellano D; Virizuela JA; Cruz J; Sepulveda JM; Sáez MI; Paz-Ares L
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S29-32. PubMed ID: 22723081
[TBL] [Abstract][Full Text] [Related]
16. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
[TBL] [Abstract][Full Text] [Related]
17. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapy in renal cell cancer.
Srinivasan R; Armstrong AJ; Dahut W; George DJ
BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Sonpavde G; Willey CD; Sudarshan S
Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
